|1.||Camilleri, Michael: 3 articles (02/2013 - 10/2011)|
|2.||Trauner, Michael: 2 articles (09/2014 - 05/2010)|
|3.||Brouwer, Kim L R: 2 articles (09/2013 - 04/2006)|
|4.||Wong, Banny S: 2 articles (02/2013 - 12/2011)|
|5.||Gwak, Geum-Youn: 2 articles (02/2012 - 08/2006)|
|6.||Graffner, Hans: 2 articles (12/2011 - 10/2011)|
|7.||Lammert, F: 2 articles (08/2011 - 06/2002)|
|8.||West, Kristy L: 2 articles (01/2004 - 12/2003)|
|9.||Fernandez, Maria Luz: 2 articles (01/2004 - 12/2003)|
|10.||Keller, Bradley T: 2 articles (12/2003 - 11/2003)|
|2.||Hepatocellular Carcinoma (Hepatoma)
02/21/2012 - "A human hepatocellular carcinoma cell line stably transfected with a bile acid transporter (Huh-BAT cells), were used in this study. "
08/01/2006 - "Huh-BAT cells, a human hepatocellular carcinoma cell line stably transfected with a bile acid transporter, were used in this study. "
10/01/1997 - "Hepatocellular carcinomas express the Na(+)-dependent bile acid transporter NTCP. "
05/01/1996 - "Therapeutic strategies employing bile acid-derived cytostatic agents for the treatment of hepatocellular carcinomas may therefore depend upon the expression of the Na+-independent bile acid transporter OATP in hepatic malignancies."
09/01/2003 - "This study of endotoxinemia may thus provide a mechanistic link between GH treatment and exacerbation of cholestasis through modulation of basolateral bile acid transporter expression in the rat hepatocyte."
05/01/2010 - "Although hereditary or acquired defects in hepatobiliary transporter systems cause or predispose to cholestasis, adaptive bile acid transporter changes can counteract cholestasis by reducing hepatocellular and systemic concentrations of retained cholephiles. "
10/22/2004 - "To attenuate injury during cholestasis, adaptive changes in bile acid transporter expression in the liver provide alternative bile acid excretory pathways. "
09/01/2003 - "We hypothesized that GH might increase mortality by exacerbating cholestasis through modulation of bile acid transporter expression. "
08/01/2011 - "Therefore, patients with hemolytic disorders should be investigated for bile acid transporter diseases in case of hyperbilirubinemia and severe cholestasis."
10/01/2011 - "A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation."
06/28/2015 - "Recently, the inhibition of the ileal bile acid transporter has become a promising target for constipation-associated diseases. "
06/28/2015 - "Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation."
02/01/2013 - "Elobixibat (formerly A3309) is a first-in-class ileal bile acid transporter (IBAT) inhibitor for treatment of chronic idiopathic constipation (CIC; syn functional constipation). "
07/01/2012 - "Turning classical bile acid physiology into everyday pharmacology: impact of a bile acid transporter inhibitor on chronic constipation."
08/01/2006 - "We attempted to see if immunohistochemical and mutational-analysis studies could demonstrate that deficiency of the canalicular bile acid transporter bile salt export pump (BSEP) and mutation in ABCB11, encoding BSEP, underlay progressive familial intrahepatic cholestasis (PFIC)--or "neonatal hepatitis" suggesting PFIC--that was associated with HCC in young children. "
|1.||Carrier Proteins (Binding Protein)
|2.||progressive familial intrahepatic 1 Cholestasis
|6.||Bile Acids and Salts (Bile Acids)
|7.||sodium-bile acid cotransporter
|8.||Taurocholic Acid (Sodium Taurocholate)
|9.||Apolipoproteins B (ApoB)
|10.||1- (4- (4- (3,3- dibutyl- 7- (dimethylamino)- 2,3,4,5- tetrahydro- 4- hydroxy- 1,1- dioxido- 1- benzothiepin- 5- yl)phenoxy)butyl)- 4- aza- 1- azoniabicyclo(2.2.2)octane
|1.||Drug Therapy (Chemotherapy)